Partnering
With its strong proprietary technology position, including a broad basis of preclinical data, XL-protein focuses at the preclinical as well clinical development of PASylated proteins in several disease areas. To uncover the full potential of the PASylation technology XL-protein offers licensing opportunities on several levels.
News and Publications
XL-protein and Antlia Bioscience announce collaboration to develop long-acting peptide therapy of chronic heart failure using PASylation® Technology
15. October 2020
XL-protein and DNX Biopharmaceuticals Announce Collaboration to Develop Novel Inflammasome-Directed Therapeutics using PASylation® Technology
25. February 2020